Medpace Holdings, Inc. (MEDP) has strong financials, growth potential, and $1 billion share buyback program.

From Yahoo Finance: 2025-05-21 11:27:00

Medpace Holdings, Inc. (MEDP) is trading at $305.98 and has a trailing P/E of 23.36 and forward P/E of 24.88. Founded in 1992, Medpace is a global clinical research organization with a focus on oncology and cardiology. The company has strong financials, a $2.85 billion backlog, and a $1 billion share buyback program.

The CRO industry is expected to grow to $71 billion by 2024. Medpace caters to small and mid-sized biotech firms, with proprietary technology like ClinTrak and AI-driven imaging analytics. Despite near-term challenges, Medpace’s global presence and client relationships provide long-term resilience. Valuation suggests conservative growth and a 12.2% annual return.

42 hedge funds held MEDP at the end of Q4, compared to 41 in the previous quarter. While MEDP offers an investment opportunity, some AI stocks may deliver higher returns in a shorter timeframe. Consider exploring AI stocks trading at less than 5 times earnings for promising investment opportunities.



Read more at Yahoo Finance: Medpace Holdings, Inc. (MEDP): A Bull Case Theory